Autonomix Medical, Inc. (AMIX) intrinsic value & 10-year financials
Autonomix Medical, Inc. (AMIX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue reached to $0, with an average return on invested capital of -208.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.85
- Revenue (FY2026)
- $0
- ROIC (10-yr avg)
- -208.6%
- Free cash flow (FY2026)
- -$12.3M
AMIX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $0 | -$16.7M | — | -$12.3M | — | -243.4% |
| FY2025 | $0 | -$11.4M | — | -$8.3M | — | -147.4% |
| FY2024 | $0 | -$15.4M | — | -$6.7M | — | -290.9% |
| FY2023 | $0 | -$2.0M | — | -$1.9M | — | -152.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Autonomix Medical, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Autonomix Medical, Inc. has historically struggled to out-earn its cost of capital, averaging just -38.6% ROIC.
Autonomix Medical, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Autonomix Medical, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.